Avanir Gives Preliminary Q1 Update - Analyst Blog

A generic image of a pen, a calculator and papers
Credit: Shutterstock photo

Avanir Pharmaceuticals, Inc. ( AVNR ) announced preliminary results for the first quarter of fiscal 2014 (year ending in Sep 2014) with gross revenues of roughly $34.6 million ahead of the Zacks Consensus Estimate of $24 million.

Avanir expects first quarter gross Nuedexta revenues to grow around 13% sequentially to $31.3 million. Nuedexta is approved for the treatment of patients suffering from pseudobulbar affect (PBA). Avanir expects Nuedexta net revenues to grow 15%-18% sequentially.

In the reported quarter, Avanir expects cash and cash equivalents, investments and cash used in operating activities around $43.9 million, $2.6 million and $9.5 million respectively.

Avanir is looking to expand Nuedexta's label. Nuedexta is currently being studied for two additional indications in phase II, namely, AVR-131 study - for the treatment of agitation in Alzheimer's disease (second half calendar 2014) and AVR-133 study - for levodopa induced dyskinesia (LID) in patients suffering from Parkinson's disease (second half calendar 2014).

We note that in Dec 2013, share price of Avanir fell 2.5% on the failure of phase II, PRIME study. The PRIME study on Nuedexta for the treatment of central neuropathic pain in patients with multiple sclerosis failed to achieve the primary endpoint. Patients treated with Nuedexta experienced similar levels of pain reduction as compared to placebo.

Avanir carries a Zacks Rank #3 (Hold). The share price of Avanir jumped 9.9% on the announcement of the preliminary results. Other better-ranked players in the pharma industry include Lannett Company, Inc. ( LCI ), WuXi PharmaTech (Cayman) Inc. ( WX ) and Jazz Pharmaceuticals Inc. ( JAZZ ). All the three stocks carry a Zacks Rank #1 (Strong Buy).

AVANIR PHARM (AVNR): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More